- Latest week
- 11 Sep 2026
- Weekly close
- 1.94 USD
- Fair value
- 1.78 USD
Seven-day news read · 13–19 September 2026
Recent company news leans cautious
Negative company coverage has outnumbered positive coverage across the last seven days.
Company-specific coverage
The news behind the seven-day read
Newest first. The seven-day balance describes these headlines; the weighted score uses a longer 30-day evidence window.
- Investing.com · Main companyCentury Therapeutics SVP Douglas Carr sells $3,199 in shares
- Investing.com · Main companyCentury Therapeutics CTO Gregory Russotti sells $4,992 in stock
- stocktitan.net · Main companyCentury Therapeutics (IPSC) exec sale covers RSU taxes
- stocktitan.net · Main companyCentury Therapeutics (IPSC) insider sale only covers tax withholding
- Stock Titan · Main companyCentury Therapeutics (NASDAQ: IPSC) officer intends $4,994 sale of stock
- stocktitan.net · Main companyCentury Therapeutics (NASDAQ: IPSC) officer lines up 1,658-share stock sale
Keep the two readings separate
Recent news shows what changed; the score shows the wider tone
A simple description of company headlines published during 13–19 September 2026.
A 30-day reading that gives more weight to newer, directly relevant coverage.